Asclepix Therapeutics, Inc.
Immunoactivating peptide AXT201 that inhibits VEGFR2 signaling and activates Tie2 signaling to normalize tumor vasculature and enhance anti-tumor immunity in combination with anti-PD-1 checkpoint inhi
- Sector
- Biotech
- Headquarters
- Bethesda, MD
- Founded
- 2023
- Latest Form D
- $10M, Apr 2024
- Total capital
- $28.1M
- Federal grants
- $4M
- 7 awards · 2015–2019
- Rank in peer group#242 of 514
- Private capital raised
- $24.1M
- 4 Form D · last Apr 2024
- 30 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 8 pending · first 2023
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$10M
- Private capital raisedForm D · SEC · 3rd filing$10M
- Federal grantHealth and Human S · Phase I · Immunoactivating Peptide AXT201 in Combination with Anti-PD-1 Antibody for Triple-Negative Breast Cancer$300K
- Private capital raisedForm D · SEC · 2nd filing$3.9M
- Federal grantHealth and Human S · Phase II · IND-enabling development of a biomimetic peptide drug for macular edema$107K
- Federal grantHealth and Human S · Phase I · Therapeutic peptide for hepatocellular carcinoma$300K
- Federal grantHealth and Human S · Phase II · IND-enabling development of a biomimetic peptide drug for macular edema$824K
- Private capital raisedForm D · SEC · 1st filing$175K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · IND-enabling development of a biomimetic peptide drug for macular edema$2.1M
- Federal grantHealth and Human S · Phase I · Development of a mimetic multimodal peptide for the treatment of macular edema$278K
- Federal grantHealth and Human S · Phase I · Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD$71K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
20months
from Asclepix Therapeutics, Inc.’s first federal award to its first private round.
- First federal award · Jun 2015
- Health and Human S · $71K
- First Form D · Feb 2017
- $175K · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#242 · top 47%
- Granted patents#142 · top 28%
- Linked publications#53 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Niranjan PandeyResearcherExecutive OfficerLinked by 1 patent · $2.4M in grants as PI
- Aleksander PopelExecutive OfficerNamed in SEC Form D filings
- Aleksander S. Popel, PhDExecutive Officer, DirectorNamed in SEC Form D filings
- Amir ShojaeiExecutive OfficerNamed in SEC Form D filings
- Ben AskewDirectorNamed in SEC Form D filings
- Chris GarabedianDirectorNamed in SEC Form D filings
Show all 16 people
- Jill TierneyExecutive OfficerNamed in SEC Form D filings
- Jordan GreenDirectorNamed in SEC Form D filings
- Josh BarerDirectorNamed in SEC Form D filings
- Joshua S. BarerDirectorNamed in SEC Form D filings
- Kevin S. Slawin, MDExecutive Officer, DirectorNamed in SEC Form D filings
- Robert DempseyExecutive OfficerNamed in SEC Form D filings
- Sapna S. SrivastavaDirectorNamed in SEC Form D filings
- Steven AltschulerDirectorNamed in SEC Form D filings
- Steven S. Altschuler, MDDirectorNamed in SEC Form D filings
- Wendy PerrowExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 10- GrantedCompositions And Methods For Treating Ocular DiseaseUSPTOUS 12,540,171
- PendingFormulations For Intraocular Delivery Of Peptides Derived From Type IV CollagenUSPTOApplication 18439088
- GrantedMethods For Identifying And Preparing Pharmaceutical Agents For Activating TIE1 And/or TIE2 ReceptorsUSPTOUS 11,674,959
Show all 10 patent records
- Compositions And Methods For Treating Ocular DiseaseFeb 3, 2026 · US 12,540,171Granted
- Formulations For Intraocular Delivery Of Peptides Derived From Type IV CollagenJul 11, 2024 · Application 18439088Pending
- Methods For Identifying And Preparing Pharmaceutical Agents For Activating TIE1 And/or TIE2 ReceptorsJun 13, 2023 · US 11,674,959Granted
- Biodegradable Microparticles For Sustained Delivery Of Anti-angiogenic PeptideJun 11, 2020 · Application 16612124Pending
- Compositions And Methods For Treating Ocular DiseaseApplication PCTUS2020024972Pending
- Formulations For Intraocular Delivery Of Peptides Derived From Type IV CollagenApplication PCTUS2023072905Pending
- Formulations For Intraocular Delivery Of Peptides Derived From Type IV CollagenApplication 63401395Pending
- Compositions And Methods For Treatment Of CancerApplication PCTUS2019027820Pending
- Compositions And Methods For Treating Ocular DiseaseApplication 62824017Pending
- Formulations For Intraocular Delivery Of Peptides Derived From Type IV CollagenApplication 19105910Pending
Recent research by its founders
- Suprachoroidal Delivery of Anti-Angiogenic Peptide Microparticles Enables Sustained Activity with Favorable Ocular Safety20260 cites
- Oncolytic peptide NF27 effectively inhibits tumor growth and eradicates tumors in multiple cancer types20250 cites
- Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth20248 cites
Related companies, and why
- Arrowhead PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Roivant SciencesSimilar federal contract value in Biotech · null in contracts
- ALTBIOTICS LLCSimilar federal contract value in Biotech · null in contracts
- BEHAVIORCLOUD, LLCSimilar federal contract value in Biotech · null in contracts
- IQ PROTEOMICS, LLCSimilar federal contract value in Biotech · null in contracts
- CELETRIX, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .